ATRS Antares Pharma Inc.

2.69
+0.04  (+2%)
Previous Close 2.65
Open 2.65
52 Week Low 1.6
52 Week High 5.13
Market Cap $446,792,521
Shares 166,093,874
Float 148,967,260
Enterprise Value $441,063,521
Volume 616,846
Av. Daily Volume 939,775
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Selatogrel and QuickShot
Acute myocardial infarction (AMI)
Phase 1
Phase 1
Phase 2 trial planned for 2020.
XYOSTED (testosterone enanthate)
Testosterone deficiency
Approved
Approved
FDA Approval announced October 1, 2018.
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy
Approved
Approved
Approval announced February 14, 2018.
OTREXUP
Rheumatoid arthritis (RA)
Approved
Approved
Approved Oct 14, 2013.
Anturol
Overactive bladder
Approved
Approved
Approved December 8, 2011.

Latest News

  1. EWING, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference.

    Details of the presentation are as follows:

    Event:H.C. Wainwright 22nd Annual Global Virtual Investment Conference
    Format:Fireside Chat and 1x1 Meetings
    Fireside Chat Date:Monday, September 14, 2020
    Fireside Chat Time:1:30pm ET

    A live webcast of the fireside chat will be available under the "For Investors" section of the Antares Pharma website at www.antarespharma.com.

    About Antares Pharma

    Antares Pharma, Inc. is a pharmaceutical technology…

    EWING, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference.

    Details of the presentation are as follows:

    Event:H.C. Wainwright 22nd Annual Global Virtual Investment Conference
    Format:Fireside Chat and 1x1 Meetings
    Fireside Chat Date:Monday, September 14, 2020
    Fireside Chat Time:1:30pm ET

    A live webcast of the fireside chat will be available under the "For Investors" section of the Antares Pharma website at www.antarespharma.com.

    About Antares Pharma

    Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

    SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

    This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.  Factors that may cause such differences include, but are not limited to: the uncertainty regarding the duration, scope and severity of the COVID-19 pandemic and the mitigation measures and other restrictions implemented in response to the same and the impact on reinstated 2020 full-year revenue guidance, demand for our products, new patients and prescriptions, future revenue, product supply, and our overall business, operating results and financial condition; market acceptance, adequate reimbursement coverage and commercial success of XYOSTED® and future revenue from the same; market acceptance of Teva's generic epinephrine auto-injector product and future revenue from the same; our expectations regarding whether the FDA will pursue withdrawal of approval for AMAG Pharmaceuticals Inc.'s Makena® subcutaneous auto injector following the recent FDA advisory committee meeting and future prescriptions, market acceptance and revenue from Makena® subcutaneous auto injector; Teva's ability to successfully commercialize VIBEX® Sumatriptan Injection USP and the amount of revenue from the same; continued growth of prescriptions and sales of OTREXUP®;  the timing and results of the Company's or its partners' research projects or clinical trials of product candidates in development including Idorsia Pharmaceuticals, Pfizer and Teva;  actions by the FDA or other regulatory agencies with respect to the Company's products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; the Company's ability to meet loan extension and interest only payment milestones and the ability to repay the debt obligation to Hercules Capital;  the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K, and in the Company's other periodic reports and filings with the Securities and Exchange Commission.  The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

    Contact:

    Tram Bui

    Vice President, Corporate Communications and Investor Relations

    609-359-3020

    Primary Logo

    View Full Article Hide Full Article
  2. EWING, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a pharmaceutical technology company, today announced the appointment of Tram Bui as Vice President of Corporate Communications and Investor Relations.  Ms. Bui will succeed Jack Howarth, Vice President of Corporate Affairs, upon his retirement on August 31, 2020. Tram will report to Fred Powell, Antares Pharma's Chief Financial Officer.

    "I am excited to welcome Tram to Antares to lead our corporate communications and investor relations strategy. We look forward to leveraging her extensive industry experience and strong relationships with the investment community as the Company continues on its growth trajectory," said Fred M. Powell, Executive…

    EWING, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a pharmaceutical technology company, today announced the appointment of Tram Bui as Vice President of Corporate Communications and Investor Relations.  Ms. Bui will succeed Jack Howarth, Vice President of Corporate Affairs, upon his retirement on August 31, 2020. Tram will report to Fred Powell, Antares Pharma's Chief Financial Officer.

    "I am excited to welcome Tram to Antares to lead our corporate communications and investor relations strategy. We look forward to leveraging her extensive industry experience and strong relationships with the investment community as the Company continues on its growth trajectory," said Fred M. Powell, Executive Vice President and Chief Financial Officer of the Company. "I would also like to thank Jack for his dedication and many contributions to the company since 2012. He has been instrumental to the development of the Company's communications strategy and we wish him the best of luck in his retirement."  

    Ms. Bui joins Antares Pharma with over 15 years of equity research, communications and investor relations experience. Most recently, she served as Senior Vice President, Investor Relations at The Ruth Group, a boutique investor relations and communications firm specializing in life science and medical technology industries.  Prior to The Ruth Group, Ms. Bui served as a Director at KCSA Strategic Communications, a public and investor relations agency, focused on developing successful investor communications platforms and capital raises for a broad base of public healthcare companies.  Previously, she was a buy-side healthcare analyst for a small cap fund at Lazard Asset Management and served as an institutional equity sales associate at CJS Securities. Ms. Bui received her Bachelor of Science in Marketing from the University of New Orleans.

    About Antares Pharma

    Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia).  Antares Pharma's FDA approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

    SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

    This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.  Factors that may cause such differences include, but are not limited to: Teva's successful commercialization of teriparatide injection in Europe and future revenue from the same; the uncertainty regarding the duration, scope and severity of the COVID-19 pandemic and the mitigation measures and other restrictions implemented in response to the same and the impact on reinstated 2020 full-year revenue guidance, demand for our products, new patients and prescriptions, future revenue, product supply, and our overall business, operating results and financial condition; market acceptance, adequate reimbursement coverage and commercial success of XYOSTED® and future revenue from the same; successful development including the timing and results of the clinical bridging and Phase 3 clinical trial of the drug device combination product for Selatogrel with Idorsia Pharmaceuticals and FDA and global regulatory approvals and future revenue from the same; market acceptance of Teva's generic epinephrine auto-injector product and future revenue from the same; the ability of Lunatus to obtain regulatory approvals for XYOSTED in Saudi Arabia and UAE and successfully commercialize the product and future revenue from the same; our expectations regarding whether the FDA will pursue withdrawal of approval for AMAG Pharmaceuticals Inc.'s Makena® subcutaneous auto injector following the recent FDA advisory committee meeting and future prescriptions, market acceptance and revenue from Makena® subcutaneous auto injector; Teva's ability to successfully commercialize VIBEX® Sumatriptan Injection USP and the amount of revenue from the same; continued growth of prescriptions and sales of OTREXUP®;  the timing and results of the Company's or its partners' research projects or clinical trials of product candidates in development; actions by the FDA or other regulatory agencies with respect to the Company's products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; the Company's ability to meet loan extension and interest only payment milestones and the ability to repay the debt obligation to Hercules Capital;  the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K, and in the Company's other periodic reports and filings with the Securities and Exchange Commission.  The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

    Contact:

    Tram Bui

    Vice President, Corporate Communications and Investor Relations

    609-359-3020

    Primary Logo

    View Full Article Hide Full Article
    • Second Quarter 2020 Revenue of $32.4 Million, a 14% Increase Compared to Second Quarter 2019

    • Second Quarter 2020 Net Income of $2.2 Million as Compared to Net Loss of $2.2 Million for Second Quarter 2019
       
    • Reinstates Full-Year 2020 Revenue Guidance Range of $135 to $155 Million

    EWING, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a pharmaceutical technology company, today reported operating and financial results for the second quarter ended June 30, 2020 with record second quarter revenue of $32.4 million and net income of $2.2 million, or earnings per share of $0.01.  The Company also reported record six-month year-to-date revenue of $65.5 million, a 27% increase versus the first six months of 2019…

    • Second Quarter 2020 Revenue of $32.4 Million, a 14% Increase Compared to Second Quarter 2019



    • Second Quarter 2020 Net Income of $2.2 Million as Compared to Net Loss of $2.2 Million for Second Quarter 2019

       
    • Reinstates Full-Year 2020 Revenue Guidance Range of $135 to $155 Million

    EWING, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a pharmaceutical technology company, today reported operating and financial results for the second quarter ended June 30, 2020 with record second quarter revenue of $32.4 million and net income of $2.2 million, or earnings per share of $0.01.  The Company also reported record six-month year-to-date revenue of $65.5 million, a 27% increase versus the first six months of 2019.

    "I am very proud of the Antares team for delivering strong quarterly results while navigating the challenges presented by the COVID-19 pandemic. We remain committed to protecting the health and safety of our employees, patients, and health care providers while effectively operating our business to meet the needs of our partners and patients during this unprecedented time. The Company's second quarter revenue of $32.4 million, which represents 14% year-over-year growth, was primarily driven by our proprietary product XYOSTED. The second quarter had the highest number of XYOSTED prescriptions to date, and we believe this is the result of the tremendous execution by our commercial team and highlights the demand for an easy to use, painless at-home testosterone injection option given limited physician and patient access at this time. Revenue from proprietary products, XYOSTED and OTREXUP, our highest margin products, grew 65% in the quarter versus the same period last year and now represent 60% of our total product revenue," said Robert F. Apple, President and Chief Executive Officer of the Company.

    "We also continued to advance our product pipeline with the recently launched Teriparatide Injection ("teriparatide") by Teva, the generic version of Eli Lilly's brand Forsteo, in Canada and certain countries in Europe. According to Teva, the initial launch of teriparatide, which utilizes our multi-dose pen technology, will expand into other European countries later this year.  Additionally, we look forward to a potential U.S. approval of a generic Forteo later this year. Finally, while the pandemic continues to pose some uncertainty for the second half of the year, we are encouraged by the growth of our business and the opportunities ahead, and therefore we have reinstated our revenue guidance for the full year," Mr. Apple concluded.

    Second Quarter 2020 and Recent Highlights

    • Reported second quarter total 2020 revenue of $32.4 million, an increase of 14% compared to the same period last year.  Proprietary product revenue increased 65% to $14.8 million as compared to $9.0 million in the second quarter of 2019.  Reported second quarter 2020 earnings per share of $0.01 as compared to a $0.01 loss per share reported in the comparable period last year.

       
    • According to Symphony Health Solutions, XYOSTED® total prescriptions increased 11% sequentially versus the first quarter of 2020.  Since the product launched, more than one hundred thirty-two thousand prescriptions of XYOSTED® have been written by almost six thousand different physicians.

       
    • Announced the first commercial product using Antares Pharma's multi-dose pen platform was launched by the Company's development partner Teva Pharmaceutical Industries, Ltd.  Teriparatide Injection, the generic version of Eli Lilly's brand product Forsteo® was launched in Austria, Croatia, Denmark, Hungary, Ireland, The Netherlands, Portugal, Sweden, Switzerland, The United Kingdom as well as Canada and Israel.  Teva has indicated they expect to launch in other European countries later this year.

       
    • Announced an exclusive distribution agreement with Lunatus Global Medical Supplies to register, promote and distribute XYOSTED® in Saudi Arabia and the United Arab Emirates.

       
    • Cash, cash equivalents and short-term investments increased to $51.6 million at June 30, 2020, compared to $45.7 million at December 31, 2019.

    Second Quarter 2020 Financial Results

    Total revenue generated from product sales, development activities and royalties was $32.4 million for the three months ended June 30, 2020, a 14% increase compared to $28.4 million in the same period in 2019.  For the six months ended June 30, 2020, total revenue was $65.5 million, a 27% increase from $51.7 million for the comparable period in 2019.

    Product sales were $24.7 million for the three months ended June 30, 2020, a 20% increase compared to $20.6 million for the same period in 2019.  For the six-month period ended June 30, 2020, product sales were $51.8 million, a 33% increase from $38.9 million in the comparable period in 2019.   

    Sales of our proprietary products XYOSTED® and OTREXUP® generated revenue of $14.8 million and $27.4 million for the three and six months ended June 30, 2020, respectively, as compared to $9.0 million and $13.8 million for the three and six months ended June 30, 2019, respectively. The 65% and 99% increase in proprietary product sales for the three and six months ended June 30, 2020 respectively, compared to the three and six months ended June 30, 2019 were principally attributable to sales of XYOSTED®

    Partnered device sales were $9.8 million and $11.6 million for the three months ended June 30, 2020 and 2019, respectively, and $24.4 million and $25.2 million for the six months ended June 30, 2020 and 2019, respectively. The decrease in sales of partnered products for the three and six months ended June 30, 2020 as compared to the same period in 2019 is primarily attributable to a decrease in sales of needle-free devices to Ferring, and a decrease in sales of Sumatriptan Injection USP and  teriparatide devices to Teva.  Antares previously announced the divestiture of the needle-free device to Ferring and shipment of pre-launch quantities of teriparatide devices to Teva during the first two quarters of 2019.

    Licensing and development revenue was $2.7 million and $4.4 million for the three and six-month periods ended June 30, 2020, respectively, compared to $2.2 million and $3.2 million for the comparable periods in 2019, respectively.  Licensing and development revenue for the three and six- month periods was primarily from the Pfizer rescue pen and the Idorsia selatogrel pen development programs.

    Royalty revenue was $5.0 million for the three months ended June 30, 2020 compared to $5.6 million for the same period in 2019.  For the six-month period ended June 30, 2020, royalty revenue was $9.3 million, compared to $9.6 million for the same period in 2019.  The decrease in royalty revenue for the three and six-month periods were primarily attributable to a decline in royalties recognized from AMAG on their net sales of the Makena® subcutaneous auto injector.

    Operating expenses were $16.9 million for the second quarter of 2020 compared to $17.6 million in the comparable period of 2019.  Total operating expenses for the six months ended June 30, 2020 were $36.3 million as compared to $34.9 million for the comparable period in 2019.  The increase in operating expenses for the six-month period of 2020 as compared to the same period in 2019 was primarily attributable to increased head count as well as increased non-cash incentive compensation expense.

    Net income was $2.2 million, or $0.01 per share for the second quarter of 2020, compared to a net loss of $2.2 million, or $0.01 per share in the same period in 2019.  Net loss was $0.2 million, or $0.00 per share for the six months ended June 30, 2020 compared to a net loss of $7.8 million, or $0.05 per share in the comparable period of 2019. 

    At June 30, 2020, cash, cash equivalents and short-term investments were $51.6 million compared to $45.7 million at December 31, 2019.

    2020 Financial Guidance

    The Company today reinstated 2020 full-year revenue guidance in a range of $135 to $155 million, which represents a 9% to 25% year-over-year growth rate.  Given the unprecedented and unpredictable environment created by the COVID-19 pandemic, we reserve the right to revisit revenue guidance at some future point in time.

    Webcast and Conference Call Information

    Antares executives will provide a Company update and review second quarter 2020 financial results via webcast and conference call today, August 6, 2020, at 8:30 a.m. ET (Eastern Time).  The webcast of the conference call, which will include a slide presentation, can be accessed through the link located on the "For Investors" section of the Company's website (www.antarespharma.com) under "Webcasts & Presentations".  Alternatively, callers may participate in the audio portion of the conference call by dialing toll free 1-800-353-6461, or 1-334-323-0501.  Callers should reference the Antares Pharma conference call or conference identification code 5888699.  Callers can access the slide presentation on the "For Investors" section of the Company's website under "Webcasts & Presentations". 

    A telephone replay of the conference call will be available from 11:30 a.m. ET on Thursday, August 6, 2020 through 11:30 a.m. ET on Saturday, September 5, 2020.  To access the replay, callers should dial 1-888-203-1112 or 1-719-457-0820 and enter passcode 5888699. 

    About Antares Pharma

    Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia).  Antares Pharma's FDA approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

    SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

    This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.  Factors that may cause such differences include, but are not limited to: Teva's successful commercialization of teriparatide injection in Europe and future revenue from the same; the uncertainty regarding the duration, scope and severity of the COVID-19 pandemic and the mitigation measures and other restrictions implemented in response to the same and the impact on reinstated 2020 full-year revenue guidance, demand for our products, new patients and prescriptions, future revenue, product supply, and our overall business, operating results and financial condition; market acceptance, adequate reimbursement coverage and commercial success of XYOSTED® and future revenue from the same; successful development including the timing and results of the clinical bridging and Phase 3 clinical trial of the drug device combination product for Selatogrel with Idorsia Pharmaceuticals and FDA and global regulatory approvals and future revenue from the same; market acceptance of Teva's generic epinephrine auto-injector product and future revenue from the same; the ability of Lunatus to obtain regulatory approvals for XYOSTED® in Saudi Arabia and UAE and successfully commercialize the product and future revenue from the same; our expectations regarding whether the FDA will pursue withdrawal of approval for AMAG Pharmaceuticals Inc.'s Makena® subcutaneous auto injector following the recent FDA advisory committee meeting and future prescriptions, market acceptance and revenue from Makena® subcutaneous auto injector; Teva's ability to successfully commercialize VIBEX® Sumatriptan Injection USP and the amount of revenue from the same; continued growth of prescriptions and sales of OTREXUP®;  the timing and results of the Company's or its partners' research projects or clinical trials of product candidates in development;  actions by the FDA or other regulatory agencies with respect to the Company's products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; the Company's ability to meet loan extension and interest only payment milestones and the ability to repay the debt obligation to Hercules Capital;  the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K, and in the Company's other periodic reports and filings with the Securities and Exchange Commission.  The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

    Contact:

    Jack Howarth

    Vice President, Corporate Affairs

    609-359-3016



    ANTARES PHARMA, INC.

    Table 1 - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

    (amounts in thousands except per share amounts)

    (unaudited)

      Three Months Ended      Six Months Ended     
      June 30,  Increase  June 30,  Increase 
      2020  2019  (Decrease)  2020  2019  (Decrease) 
    Revenue:                        
    Product sales $24,665  $20,620  20%  $51,762  $38,920  33% 
    Licensing and development revenue  2,687   2,239  20%   4,442   3,154  41% 
    Royalties  5,032   5,574  -10%   9,259   9,645  -4% 
    Total revenue  32,384   28,433  14%   65,463   51,719  27% 
    Cost of Revenue  12,477   12,441  0%   27,524   23,387  18% 
    Gross profit  19,907   15,992  24%   37,939   28,332  34% 
    Research and development  2,417   2,494  -3%   5,398   4,881  11% 
    Selling, general and administrative  14,448   15,087  -4%   30,870   30,022  3% 
    Total operating expenses  16,865   17,581  -4%   36,268   34,903  4% 
    Operating income (loss)  3,042   (1,589) **   1,671   (6,571) ** 
    Other expense  (867)  (637) 36%   (1,852)  (1,194) 55% 
    Net income (loss) $2,175  $(2,226) **  $(181) $(7,765) -98% 
    Net income (loss) per common share, basic and diluted $0.01  $(0.01)     $(0.00) $(0.05)    
    Weighted average common shares outstanding:                        
    Basic  165,703   162,734       165,566   161,596     
    Diluted  169,228   162,734       165,566   161,596     
                             





    ANTARES PHARMA, INC.

    Table 2 – CONSOLIDATED DETAIL OF REVENUE FROM PRODUCT SALES

    (amounts in thousands)

    (unaudited)

      Three Months Ended  Six Months Ended 
      June 30,  June 30, 
      2020  2019  2020  2019 
    Product sales:                
    XYOSTED® $10,902  $4,623  $19,905  $5,326 
    OTREXUP®  3,944   4,361   7,507   8,429 
    Partnered product sales  9,819   11,636   24,350   25,165 
    Total product sales $24,665  $20,620  $51,762  $38,920 
                     





    ANTARES PHARMA, INC.

    Table 3 – CONSOLIDATED CONDENSED BALANCE SHEETS

    (amounts in thousands)

    (unaudited)

      June 30,  December 31, 
      2020  2019 
    Assets        
    Cash, cash equivalents and investments $51,550  $45,721 
    Accounts receivable  34,293   35,074 
    Inventories  19,605   16,000 
    Contract assets  7,013   8,235 
    Equipment, molds, furniture and fixtures, net  19,452   15,961 
    Right of use assets  4,860   5,463 
    Other assets  6,351   6,297 
    Total Assets $143,124  $132,751 
             
    Liabilities and Stockholders' Equity        
    Accounts payable and accrued expenses $37,633  $30,677 
    Deferred revenue  2,341   1,738 
    Long-term debt and other liabilities  45,821   45,836 
    Stockholders' equity  57,329   54,500 
    Total Liabilities and Stockholders' Equity $143,124  $132,751 
             

    Primary Logo

    View Full Article Hide Full Article
  3. EWING, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS), a pharmaceutical technology company, today announced they have entered into an exclusive distribution agreement with Lunatus Global Medical Supplies ("Lunatus") to distribute and promote the sale of  XYOSTED® in Saudi Arabia and the United Arab Emirates ("UAE"). 

    Under the agreement, Antares will be responsible for the supply of fully packaged product to Lunatus and Lunatus will be responsible for submitting and obtaining regulatory approval for XYOSTED® in Saudi Arabia and the UAE as well as marketing, promotion and distribution of XYOSTED® in these two countries.

    "We believe today's announcement represents the first step in creating increased brand awareness…

    EWING, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS), a pharmaceutical technology company, today announced they have entered into an exclusive distribution agreement with Lunatus Global Medical Supplies ("Lunatus") to distribute and promote the sale of  XYOSTED® in Saudi Arabia and the United Arab Emirates ("UAE"). 

    Under the agreement, Antares will be responsible for the supply of fully packaged product to Lunatus and Lunatus will be responsible for submitting and obtaining regulatory approval for XYOSTED® in Saudi Arabia and the UAE as well as marketing, promotion and distribution of XYOSTED® in these two countries.

    "We believe today's announcement represents the first step in creating increased brand awareness for XYOSTED in the rest of the world, and look forward to working with our partner Lunatus in that endeavour.  XYOSTED is currently the fastest growing branded testosterone replacement therapy in the U.S.," said Robert F. Apple, President and Chief Executive Officer of the Company."  He continued, "Current treatment options in these two countries include a painful hospital administered testosterone injection given every three months or a topical gel.  Alternatively, XYOSTED would be an attractive new treatment option for physicians and patients given its unique product profile featuring a virtually painless, once-weekly, at-home subcutaneous self-injection.  Lunatus, a Dubai based company, has a proven track record of introducing, building and maintaining profitable brands in the Arabian Gulf and Middle East regions.  We believe this agreement will help lay the groundwork for expanding our global footprint for XYOSTED and represents the first of potentially multiple international distribution agreements."

    "We are excited to bring XYOSTED to Saudi Arabia and the UAE.  XYOSTED is a U.S. FDA approved treatment option for adult men diagnosed with testosterone deficiency," said Dr. Lina Kouatly, President and Chief Executive Officer of Lunatus.  "Assuming regulatory approval in these two countries, we believe our partnership can achieve significant share and expand the market using this novel treatment approach."  

    About Antares Pharma

    Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia).  Antares Pharma's proprietary products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

    SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

    This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.  Factors that may cause such differences include, but are not limited to: Lunatus' ability to obtain regulatory approval and successfully commercialize XYOSTED in Saudi Arabia and the United Arab Emirates and the amount of revenue from the same, the uncertainty regarding the duration, scope and severity of the COVID-19 pandemic and the mitigation measures and other restrictions implemented in response to the same and the impact on demand for our products, new patients and prescriptions, future revenue, product supply, and our overall business, operating results and financial condition; market acceptance, adequate reimbursement coverage and commercial success of XYOSTED® and future revenue from the same; successful development including the timing and results of the clinical bridging and Phase 3 clinical trial of the drug device combination product for Selatogrel with Idorsia Pharmaceuticals and FDA and global regulatory approvals and future revenue from the same; market acceptance of Teva's generic epinephrine auto-injector product and future revenue from the same; our expectations regarding whether the FDA will pursue withdrawal of approval for AMAG Pharmaceuticals Inc.'s Makena® subcutaneous auto injector following the recent FDA advisory committee meeting and future prescriptions, market acceptance and revenue from Makena® subcutaneous auto injector; Teva's ability to successfully commercialize VIBEX® Sumatriptan Injection USP and the amount of revenue from the same; continued growth of prescriptions and sales of OTREXUP®;  the timing and results of the Company's or its partners' research projects or clinical trials of product candidates in development;  actions by the FDA or other regulatory agencies with respect to the Company's products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; the Company's ability to meet loan extension and interest only payment milestones and the ability to repay the debt obligation to Hercules Capital;  the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K, and in the Company's other periodic reports and filings with the Securities and Exchange Commission.  The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

    Contacts:

    Jack Howarth

    Vice President, Corporate Affairs

    609-359-3016

    Primary Logo

    View Full Article Hide Full Article
  4. EWING, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS), a pharmaceutical technology company, today announced it will release its second quarter 2020 financial results and recent operating progress before the market opens on Thursday, August 6, 2020.  Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on August 6, 2020 to discuss the results.

    Interested parties may participate in the conference call by dialing 1-800-353-6461 or 1-334-323-0501 and entering access code 5888699.  We encourage interested parties to dial into the conference call at least 10 minutes prior to the scheduled start time.  A replay of the conference call will be available from 11:30 a.m. ET on Thursday, August…

    EWING, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS), a pharmaceutical technology company, today announced it will release its second quarter 2020 financial results and recent operating progress before the market opens on Thursday, August 6, 2020.  Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on August 6, 2020 to discuss the results.

    Interested parties may participate in the conference call by dialing 1-800-353-6461 or 1-334-323-0501 and entering access code 5888699.  We encourage interested parties to dial into the conference call at least 10 minutes prior to the scheduled start time.  A replay of the conference call will be available from 11:30 a.m. ET on Thursday, August 6, 2020 through 11:30 a.m. ET on Saturday, September 5, 2020 by dialing 1-888-203-1112 or 1-719-457-0820 and entering the access code 5888699.  An archive of the slide presentation will also be available under the "For Investors" section of the Antares Website at www.antarespharma.com.

    About Antares Pharma

    Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia).  Antares Pharma's proprietary products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

    SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

    This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.  Factors that may cause such differences include, but are not limited to: the uncertainty regarding the duration, scope and severity of the COVID-19 pandemic and the mitigation measures and other restrictions implemented in response to the same and the impact on demand for our products, new patients and prescriptions, future revenue, product supply, and our overall business, operating results and financial condition; market acceptance, adequate reimbursement coverage and commercial success of XYOSTED® and future revenue from the same; successful development including the timing and results of the clinical bridging and Phase 3 clinical trial of the drug device combination product for Selatogrel with Idorsia Pharmaceuticals and FDA and global regulatory approvals and future revenue from the same; market acceptance of Teva's generic epinephrine auto-injector product and future revenue from the same; our expectations regarding whether the FDA will pursue withdrawal of approval for AMAG Pharmaceuticals Inc.'s Makena® subcutaneous auto injector following the recent FDA advisory committee meeting and future prescriptions, market acceptance and revenue from Makena® subcutaneous auto injector; Teva's ability to successfully commercialize VIBEX® Sumatriptan Injection USP and the amount of revenue from the same; continued growth of prescriptions and sales of OTREXUP®;  the timing and results of the Company's or its partners' research projects or clinical trials of product candidates in development;  actions by the FDA or other regulatory agencies with respect to the Company's products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; the Company's ability to meet loan extension and interest only payment milestones and the ability to repay the debt obligation to Hercules Capital;  the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K, and in the Company's other periodic reports and filings with the Securities and Exchange Commission.  The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

    Contacts:

    Jack Howarth

    Vice President, Corporate Affairs

    609-359-3016

    Primary Logo

    View Full Article Hide Full Article
View All Antares Pharma Inc. News